Related Experiment Videos
99mTc anti-D-dimer MoAb detects venous thrombi in man
G Merlino1, A Soluri, F La Torre
1Istituto di Tecnologia Biomedica, CNR, Roma.
Il Giornale Di Chirurgia
|January 22, 1998
Summary
Technetium-99m labeled anti-D-Dimer monoclonal antibody (MoAb) effectively visualizes thrombi in patients. This imaging agent shows promise for localizing deep vein thrombosis and aiding in surgical planning.
Area of Science:
- Nuclear Medicine
- Oncology
- Immunology
Background:
- D-Dimer is a specific epitope formed during fibrin cross-linking, indicating thrombosis.
- Antibody-based imaging agents offer targeted diagnostic capabilities.
Purpose of the Study:
- To evaluate the efficacy of 99mTc-labeled anti-D-Dimer monoclonal antibody (MoAb) for thrombus visualization in humans.
- To assess the safety and optimal imaging time for this novel diagnostic agent.
Main Methods:
- Five normal volunteers and five patients with leg varices received 10 mCi of 99mTc anti-D-Dimer MoAb.
- Scintigraphic imaging was performed at various time points (5, 60, 180 minutes, and 6-8 hours).
- Specific activity of exsected thrombi, vein walls, and blood samples was measured in two patients post-surgery.
Main Results:
- No adverse reactions were reported following MoAb administration.
- Twelve "hot spots" indicating thrombi were visualized, with five surgically localized and resected.
- Thrombus-to-vein wall and thrombus-to-blood ratios were measured at 2.2 ± 0.6 and 3.1 ± 0.8, respectively.
- Optimal scintigraphic images were obtained between 60 and 180 minutes post-injection.
Conclusions:
- 99mTc-labeled anti-D-Dimer MoAb is a safe and promising agent for the localization of thrombi.
- The study demonstrates the potential of targeted immunoscintigraphy for diagnosing thrombotic events.